TIDES Europe is Europe's leading conference dedicated to oligonucleotide, peptide, mRNA, and drug delivery therapeutics. Bringing together scientists, innovators, and industry leaders from across discovery, development, analytical characterization, manufacturing, and commercialization. The event provides a unique platform to exchange knowledge and explore emerging technologies shaping the future of therapeutic development.
As peptide and oligonucleotide therapeutics continue to gain momentum, analytical characterization becomes increasingly important for understanding molecular structure, ensuring quality, and supporting regulatory requirements throughout development. Bruker will showcase advanced NMR solutions designed to provide structural insights across the TIDES workflow, from early research to late-stage development and quality control.
Peptide Diversity and Therapeutics by NMR: Scalable Methods from Early Sequences to Drug Candidates
November 5, 2026 | 11:50 AM
This presentation explores scalable NMR approaches for peptide characterization, illustrated through case studies spanning short model peptides, long sequences, and an oncology‑relevant therapeutic candidate. We discuss practical strategies to handle sequence length, chemical diversity, and experimental complexity, highlighting how standardized, automation‑ready workflows improve robustness, reproducibility, and throughput in peptide‑focused drug discovery from early research to late‑stage development.
Shubhadra Pillay
Structural Biologist and Solutions Product Manager at Bruker BioSpin
Specialized in protein NMR spectroscopy, molecular biophysics, and structure-based drug design. She earned her PhD from Nanyang Technological University (Singapore) and completed postdoctoral training at the Max Planck Institute for Biophysical Chemistry, focusing on protein dynamics. Dr. Pillay has contributed to the structural characterization of diverse biological systems, including viral fusion proteins and transcription-related complexes, and previously co-led biophysics efforts in fragment-based drug discovery at Takeda Pharmaceuticals. Her work bridges academic research and industry-driven pharmaceutical innovation.
At Booth 225, Bruker specialists will be available to discuss analytical solutions supporting peptide and oligonucleotide research and development.